Enter your email address
Submit
Write your message
Volume 19, Issue 1 (Iranian Journal of Breast Diseases 2027)
ijbd 2027, 19(1): 49-63 |
Back to browse issues page
Ethics code: IR.MODARES.REC.1398.047
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Nazemi Zadeh A, Karami Tehrani F S, Atri M. The expression of HGPRTase in the malignant and benign breast tumors: The correlation with clinicopathological status. ijbd 2027; 19 (1) :49-63
URL: http://ijbd.ir/article-1-1190-en.html
URL: http://ijbd.ir/article-1-1190-en.html
1- Department of Clinical Biochemistry, cancer Research laboratory, Faculty of medical sciences, Tarbiat Modares University, Tehran, Iran
2- Department of Clinical Biochemistry, cancer Research laboratory, Faculty of medical sciences, Tarbiat Modares University, Tehran, Iran ,karamitf@modares.ac.ir
3- Department of Surgery, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran
2- Department of Clinical Biochemistry, cancer Research laboratory, Faculty of medical sciences, Tarbiat Modares University, Tehran, Iran ,
3- Department of Surgery, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran
Abstract: (135 Views)
Introduction: Breast cancer is the most common malignancy among women worldwide. Although several biomarkers, such as ER, PR, HER-2, and Ki-67, are routinely used for diagnosis and prognosis, there remains a need for additional markers that can reliably distinguish malignant from benign lesions. Hypoxanthine-guanine phosphoribosyl transferase 1 (HPRT1), a key enzyme in the purine salvage pathway, has been reported to be elevated in some cancers, but its role in breast cancer remains unclear.
Methods: In the present investigation, HPRT1 was evaluated in malignant (30), benign (20), and normal breast (20) tissues using Real-time PCR and western blot analysis. The correlation between the results and tumor grade (II & III), patient age, ER/PR, stage, tumor size, and Ki-67 was also assessed.
Results: Real-time PCR revealed that HPRT1 mRNA was significantly upregulated in malignant tumors compared to normal (fold change ≈ 2.1, p=0.003) and benign tissues (fold change ≈ 1.9, p=0.007). At the same time, no difference was observed between benign and normal tissues (fold change ≈ 1.1, p=0.06). Western blot analysis confirmed these findings, showing mean ± SEM expression levels of 1.28 ± 0.69 in malignant, 0.87 ± 0.05 in benign, and 0.97 ± 0.09 in normal tissues. Malignant tumors exhibited significantly higher protein expression compared to benign (p=0.002) and normal tissues (p=0.012). No significant correlations were found between HPRT1 expression and clinicopathological parameters.
Conclusions: It is concluded that elevated HPRT1 expression in malignant breast tumors provides strong evidence for its use in the diagnosis and treatment of the disease, as it is increased only in malignant, not benign, tumors.
Methods: In the present investigation, HPRT1 was evaluated in malignant (30), benign (20), and normal breast (20) tissues using Real-time PCR and western blot analysis. The correlation between the results and tumor grade (II & III), patient age, ER/PR, stage, tumor size, and Ki-67 was also assessed.
Results: Real-time PCR revealed that HPRT1 mRNA was significantly upregulated in malignant tumors compared to normal (fold change ≈ 2.1, p=0.003) and benign tissues (fold change ≈ 1.9, p=0.007). At the same time, no difference was observed between benign and normal tissues (fold change ≈ 1.1, p=0.06). Western blot analysis confirmed these findings, showing mean ± SEM expression levels of 1.28 ± 0.69 in malignant, 0.87 ± 0.05 in benign, and 0.97 ± 0.09 in normal tissues. Malignant tumors exhibited significantly higher protein expression compared to benign (p=0.002) and normal tissues (p=0.012). No significant correlations were found between HPRT1 expression and clinicopathological parameters.
Conclusions: It is concluded that elevated HPRT1 expression in malignant breast tumors provides strong evidence for its use in the diagnosis and treatment of the disease, as it is increased only in malignant, not benign, tumors.
Keywords: Breast cancer, HPRT1, Real-time PCR, Western Blot analysis, Normal breast tissue, Benign breast tissue, Malignant breast tumor
Type of Study: Research |
Subject:
molecular cell
Received: 2025/06/5 | Accepted: 2026/02/21 | Published: 2026/03/25
Received: 2025/06/5 | Accepted: 2026/02/21 | Published: 2026/03/25
References
1. M, Atri M. Evaluation of PDE5 and PDE9 expression in benign and malignant breast tumors. Archives of Medical Research. 2012;43(6):470-5. doi:10.1016/j.arcmed.2012.08.006 [DOI:10.1016/j.arcmed.2012.08.006] [PMID]
2. Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. The Lancet Global Health. 2020;8(2):e191-e203. doi:10.1016/s2214-109x(19)30482-6 [DOI:10.1016/S2214-109X(19)30482-6] [PMID] []
3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA: a cancer journal for clinicians. 2019;69(1):7-34. doi:10.3322/caac.21551 [DOI:10.3322/caac.21551] [PMID]
4. Jamalzei B, Tehrani FSK, Atri M. Evaluation of LDL receptor and Scavenger Receptor, Class B, Type 1 in the malignant and benign breast tumors: The correlation with the expression of miR-199a-5p, miR-199b-5p and miR-455-5p. Gene. 2020;749:144720. doi:10.1016/j.gene.2020.144720 [DOI:10.1016/j.gene.2020.144720] [PMID]
5. Haghighat S, Omidi Z, Ghanbari-Motlagh A. Trend of Breast Cancer Incidence in Iran During A Fifteen-Year Interval According To National Cancer Registry Reports. Iranian Journal of Breast Diseases. 2022;15(2):4-17. doi:10.30699/ijbd.15.2.4 [DOI:10.30699/ijbd.15.2.4]
6. Organization WH. International Agency for Research on Cancer Global Cancer Observatory. Cancer today. 2022.
7. Stout JT, Caskey CT. HPRT: gene structure, expression, and mutation. Annual review of genetics. 1985;19(1):127-48. doi:10.1146/annurev.ge.19.120185.001015 [DOI:10.1146/annurev.ge.19.120185.001015] [PMID]
8. Wilson JM, Tarr GE, Kelley WN. Human hypoxanthine (guanine) phosphoribosyltransferase: an amino acid substitution in a mutant form of the enzyme isolated from a patient with gout. Proceedings of the National Academy of Sciences. 1983;80(3):870-3. doi:10.1073/pnas.80.3.870 [DOI:10.1073/pnas.80.3.870] [PMID] []
9. Caskey CT, Kruh GD. The HPRT locus. Cell. 1979;16(1):1-9. doi:10.1016/0092-8674(79)90182-x [DOI:10.1016/0092-8674(79)90182-X] [PMID]
10. Townsend MH, Felsted AM, Ence ZE, Piccolo SR, Robison RA, O'Neill K. Elevated expression of hypoxanthine guanine phosphoribosyltransferase within malignant tissue. Cancer Clin Oncol. 2017;6(6):19-34. doi:10.1016/j.imbio.2020.151931 [DOI:10.1016/j.imbio.2020.151931] [PMID]
11. Sculley DG, Dawson PA, Emmerson BT, Gordon RB. A review of the molecular basis of hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency. Human genetics. 1992;90(3):195-207. doi:10.1007/bf00220062 [DOI:10.1007/BF00220062] [PMID]
12. Ding H, Yue L, Yang C. Research progress in hypoxanthine-guanine phosphoribosyltrans-ferase. Yi chuan- Hereditas. 2013;35(8):948-54. doi:10.3724/sp.j.1005.2013.00948 [DOI:10.3724/SP.J.1005.2013.00948] [PMID]
13. Fujimori S, Davidson BL, Kelley WN, Palella TD. Identification of a single nucleotide change in the hypoxanthine-guanine phosphoribosyltransferase gene (HPRTYale) responsible for Lesch-Nyhan syndrome. The Journal of Clinical Investigation. 1989;83(1):11-13. doi:10.1172/jci113846 [DOI:10.1172/JCI113846] [PMID] []
14. Fujimori S, Hidaka Y, Davidson BL, Palella TD, Kelley WN. Identification of a single nucleotide change in a mutant gene for hypoxanthine-guanine phosphoribosyltransferase (HPRT Ann Arbor). Human genetics. 1988;79(1):39-43. doi:10.1007/bf00291707 [DOI:10.1007/BF00291707] [PMID]
15. Townsend MH, Anderson MD, Weagel EG, Velazquez EJ, Weber KS, Robison RA, et al. Non-small-cell lung cancer cell lines A549 and NCI-H460 express hypoxanthine guanine phosphoribosyltransferase on the plasma membrane. OncoTargets and therapy. 2017;10:1921. doi:10.2147/ott.s128416 [DOI:10.2147/OTT.S128416] [PMID] []
16. J Sedano M, I Ramos E, Choudhari R, L Harrison A, Subramani R, Lakshmanaswamy R, et al. Hypoxanthine Phosphoribosyl Transferase 1 Is Upregulated, Predicts Clinical Outcome and Controls Gene Expression in Breast Cancer. Cancers. 2020;12(6):1522. doi:10.3390/cancers12061522 [DOI:10.3390/cancers12061522] [PMID] []
17. Townsend MH, Felsted AM, Burrup W, Robison RA, O'Neill KL. Examination of Hypoxanthine Guanine Phosphoribosyltransferase as a biomarker for colorectal cancer patients. Molecular & cellular oncology. 2018;5(4):e1481810. doi:10.1080/23723556.2018.1481810 [DOI:10.1080/23723556.2018.1481810] [PMID] []
18. Townsend MH, Robison RA, O'Neill KL. A review of HPRT and its emerging role in cancer. Medical Oncology. 2018;35(6):89. doi.org/10.1007/s12032-018-1144-1 [DOI:10.1007/s12032-018-1144-1] [PMID]
19. Townsend MH, Felsted AM, Ence ZE, Piccolo SR, Robison RA, O'Neill KL. Falling from grace: HPRT is not suitable as an endogenous control for cancer-related studies. Molecular & cellular oncology. 2019;6(2):1-10. doi.org/10.1080/23723556.2019.1575691 [DOI:10.1080/23723556.2019.1575691] [PMID] []
20. Chang Y-J, Tseng C-Y, Lin P-Y, Chuang Y-C, Chao M-W. Acute exposure to DEHP metabolite, MEHP cause genotoxicity, mutagenesis and carcinogenicity in mammalian Chinese hamster ovary cells. Carcinogenesis. 2017;38(3):336-45. doi:10.1093/carcin/bgx009 [DOI:10.1093/carcin/bgx009] [PMID]
21. Townsend MH, Ence ZE, Cox TP, Lattin JE, Burrup W, Boyer MK, et al. Evaluation of the upregulation and surface expression of hypoxanthine guanine phosphoribosyltransferase in acute lymphoblastic leukemia and Burkitt's B cell lymphoma. Cancer Cell International. 2020;20(1):375. doi:10.1186/s12935-020-01457-8 [DOI:10.1186/s12935-020-01457-8] [PMID] []
22. Townsend MH, Ence ZE, Felsted AM, Parker AC, Piccolo SR, Robison RA, et al. Potential new biomarkers for endometrial cancer. Cancer Cell International. 2019;19(1):19. doi:10.1186/s12935-019-0731-3 [DOI:10.1186/s12935-019-0731-3] [PMID] []
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
